222 related articles for article (PubMed ID: 26261062)
1. Attitudes of clinicians following large-scale pharmacogenomics implementation.
Peterson JF; Field JR; Shi Y; Schildcrout JS; Denny JC; McGregor TL; Van Driest SL; Pulley JM; Lubin IM; Laposata M; Roden DM; Clayton EW
Pharmacogenomics J; 2016 Aug; 16(4):393-8. PubMed ID: 26261062
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits.
Maranville JC; Cox NJ
Pharmacogenomics J; 2016 Aug; 16(4):388-92. PubMed ID: 26149738
[TBL] [Abstract][Full Text] [Related]
3. Patient insights on features of an effective pharmacogenomics patient portal.
Truong TM; Lipschultz E; Schierer E; Danahey K; Ratain MJ; O'Donnell PH
Pharmacogenet Genomics; 2020 Dec; 30(9):191-200. PubMed ID: 33017129
[TBL] [Abstract][Full Text] [Related]
4. Personal genome testing on physicians improves attitudes on pharmacogenomic approaches.
Lee KH; Min BJ; Kim JH
PLoS One; 2019; 14(3):e0213860. PubMed ID: 30921347
[TBL] [Abstract][Full Text] [Related]
5. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.
Gentile G; Botticelli A; Lionetto L; Mazzuca F; Simmaco M; Marchetti P; Borro M
Pharmacogenomics J; 2016 Aug; 16(4):320-5. PubMed ID: 26216193
[TBL] [Abstract][Full Text] [Related]
6. Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers.
Hachad H; Ramsey LB; Scott SA
Clin Pharmacol Ther; 2019 Aug; 106(2):298-301. PubMed ID: 31162629
[No Abstract] [Full Text] [Related]
7. Precision medicine from a citizen perspective: a survey of public attitudes towards pharmacogenomics in Flanders.
Edris A; Callier E; Lahousse L
BMC Med Genomics; 2022 Sep; 15(Suppl 3):193. PubMed ID: 36096833
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomic-Based Decision Support to Predict Adherence to Medications.
Christian C; Borden BA; Danahey K; Yeo KJ; van Wijk XMR; Ratain MJ; O'Donnell PH
Clin Pharmacol Ther; 2020 Aug; 108(2):368-376. PubMed ID: 32236960
[TBL] [Abstract][Full Text] [Related]
9. Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?
Huddart R; Sangkuhl K; Whirl-Carrillo M; Klein TE
Clin Pharmacol Ther; 2019 Aug; 106(2):284-286. PubMed ID: 30977517
[No Abstract] [Full Text] [Related]
10. Prioritizing pharmacogenomics implementation initiates: a survey of healthcare professionals.
Ho TT; Gift M; Alexander E
Per Med; 2022 Jan; 19(1):15-23. PubMed ID: 34881640
[TBL] [Abstract][Full Text] [Related]
11. Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing.
Russell C; Campion M; Grove ME; Matsuda K; Klein TE; Ashley E; Naik H; Wheeler MT; Scott SA
Clin Transl Sci; 2024 Mar; 17(3):e13737. PubMed ID: 38421234
[TBL] [Abstract][Full Text] [Related]
12. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study.
Borden BA; Galecki P; Wellmann R; Danahey K; Lee SM; Patrick-Miller L; Sorrentino MJ; Nanda R; Koyner JL; Polonsky TS; Stadler WM; Mulcahy C; Kavitt RT; Ratain MJ; Meltzer DO; O'Donnell PH
Pharmacogenet Genomics; 2019 Feb; 29(2):31-38. PubMed ID: 30531377
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.
Theken KN; Lee CR; Gong L; Caudle KE; Formea CM; Gaedigk A; Klein TE; Agúndez JAG; Grosser T
Clin Pharmacol Ther; 2020 Aug; 108(2):191-200. PubMed ID: 32189324
[TBL] [Abstract][Full Text] [Related]
14. The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
Cavallari LH; Beitelshees AL; Blake KV; Dressler LG; Duarte JD; Elsey A; Eichmeyer JN; Empey PE; Franciosi JP; Hicks JK; Holmes AM; Jeng L; Lee CR; Lima JJ; Limdi NA; Modlin J; Obeng AO; Petry N; Pratt VM; Skaar TC; Tuteja S; Voora D; Wagner M; Weitzel KW; Wilke RA; Peterson JF; Johnson JA
Clin Transl Sci; 2017 May; 10(3):143-146. PubMed ID: 28294551
[No Abstract] [Full Text] [Related]
15. Thiopurine S-methyltransferase testing for averting drug toxicity: a meta-analysis of diagnostic test accuracy.
Zur RM; Roy LM; Ito S; Beyene J; Carew C; Ungar WJ
Pharmacogenomics J; 2016 Aug; 16(4):305-11. PubMed ID: 27217052
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing the impact of pharmacogenomic prescribing on adherence to nicotine replacement therapy: A qualitative study of participants from a randomized controlled trial.
Wright AJ; Sutton S; Armstrong D; Aveyard P; Kinmonth AL; Marteau TM
Transl Behav Med; 2018 Jan; 8(1):18-28. PubMed ID: 29385578
[TBL] [Abstract][Full Text] [Related]
17. Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.
Lee YM; Danahey K; Knoebel RW; Ratain MJ; Meltzer DO; O'Donnell PH
Pharmacogenet Genomics; 2019 Feb; 29(2):23-30. PubMed ID: 30531378
[TBL] [Abstract][Full Text] [Related]
18. Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.
Xu Q; Wu X; Li M; Huang H; Minica C; Yi Z; Wang G; Shen L; Xing Q; Shi Y; He L; Qin S
Pharmacogenomics J; 2016 Aug; 16(4):357-65. PubMed ID: 26282453
[TBL] [Abstract][Full Text] [Related]
19. Investigation of community pharmacists' knowledge and attitudes of pharmacogenomics testing: implication for improved pharmacogenomic testing practice.
Ramadan A; Jarab AS; Al Meslamani AZ
Hum Genomics; 2024 Jan; 18(1):8. PubMed ID: 38291455
[TBL] [Abstract][Full Text] [Related]
20. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
